世界の神経障害薬市場予測（～2028年）：抗精神病薬、催眠薬、鎮静薬、鎮痛薬、抗凝固薬、その他

• 英文タイトル：Global Neurological Disorder Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8902 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

神経障害薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界の神経障害薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 神経障害薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・抗精神病薬、催眠薬、鎮静薬、鎮痛薬、抗凝固薬、その他 用途別セグメントは次のように区分されます。 ・病院、クリーム 世界の神経障害薬市場の主要な市場プレーヤーは以下のとおりです。 ・Novartis、GlaxoSmithKline、Merck & Co.、Bayer、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceutical 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、神経障害薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な神経障害薬メーカーの企業概要、2019年～2022年までの神経障害薬の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な神経障害薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別神経障害薬の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの神経障害薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での神経障害薬市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および神経障害薬の産業チェーンを掲載しています。 ・第13、14、15章では、神経障害薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Novartis、GlaxoSmithKline、Merck & Co.、Bayer、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceutical ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：抗精神病薬、催眠薬、鎮静薬、鎮痛薬、抗凝固薬、その他 ・用途別分析2017年-2028年：病院、クリーム ・神経障害薬の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・神経障害薬のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・神経障害薬のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・神経障害薬の南米市場規模2017年-2028年：ブラジル、アルゼンチン ・神経障害薬の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Neurological Disorder Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neurological Disorder Drugs market size is estimated to be worth US$ 19820 million in 2021 and is forecast to a readjusted size of USD 25180 million by 2028 with a CAGR of 3.5% during review period. Hospital accounting for % of the Neurological Disorder Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Antipsychotic segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neurological Disorder Drugs include Novartis, GlaxoSmithKline, Merck & Co., Bayer, and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neurological Disorder Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Market segment by Application can be divided into
Hospital
Clinic
The key market players for global Neurological Disorder Drugs market are listed below:
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neurological Disorder Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neurological Disorder Drugs, with price, sales, revenue and global market share of Neurological Disorder Drugs from 2019 to 2022.
Chapter 3, the Neurological Disorder Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurological Disorder Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neurological Disorder Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurological Disorder Drugs.
Chapter 13, 14, and 15, to describe Neurological Disorder Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Neurological Disorder Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neurological Disorder Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Antipsychotic
1.2.3 Hypnotic & Sedative
1.2.4 Analgesics
1.2.5 Anticoagulants
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Neurological Disorder Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Neurological Disorder Drugs Market Size & Forecast
1.4.1 Global Neurological Disorder Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neurological Disorder Drugs Sales in Volume (2017-2028)
1.4.3 Global Neurological Disorder Drugs Price (2017-2028)
1.5 Global Neurological Disorder Drugs Production Capacity Analysis
1.5.1 Global Neurological Disorder Drugs Total Production Capacity (2017-2028)
1.5.2 Global Neurological Disorder Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neurological Disorder Drugs Market Drivers
1.6.2 Neurological Disorder Drugs Market Restraints
1.6.3 Neurological Disorder Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Neurological Disorder Drugs Product and Services
2.1.4 Novartis Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Neurological Disorder Drugs Product and Services
2.2.4 GlaxoSmithKline Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Merck & Co.
2.3.1 Merck & Co. Details
2.3.2 Merck & Co. Major Business
2.3.3 Merck & Co. Neurological Disorder Drugs Product and Services
2.3.4 Merck & Co. Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Neurological Disorder Drugs Product and Services
2.4.4 Bayer Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Neurological Disorder Drugs Product and Services
2.5.4 AstraZeneca Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Neurological Disorder Drugs Product and Services
2.6.4 Boehringer Ingelheim Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Teva Pharmaceutical
2.7.1 Teva Pharmaceutical Details
2.7.2 Teva Pharmaceutical Major Business
2.7.3 Teva Pharmaceutical Neurological Disorder Drugs Product and Services
2.7.4 Teva Pharmaceutical Neurological Disorder Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Neurological Disorder Drugs Breakdown Data by Manufacturer
3.1 Global Neurological Disorder Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neurological Disorder Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neurological Disorder Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Neurological Disorder Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Neurological Disorder Drugs Manufacturer Market Share in 2021
3.5 Global Neurological Disorder Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neurological Disorder Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Neurological Disorder Drugs Market Size by Region
4.1.1 Global Neurological Disorder Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Neurological Disorder Drugs Revenue by Region (2017-2028)
4.2 North America Neurological Disorder Drugs Revenue (2017-2028)
4.3 Europe Neurological Disorder Drugs Revenue (2017-2028)
4.4 Asia-Pacific Neurological Disorder Drugs Revenue (2017-2028)
4.5 South America Neurological Disorder Drugs Revenue (2017-2028)
4.6 Middle East and Africa Neurological Disorder Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Neurological Disorder Drugs Sales in Volume by Type (2017-2028)
5.2 Global Neurological Disorder Drugs Revenue by Type (2017-2028)
5.3 Global Neurological Disorder Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Neurological Disorder Drugs Sales in Volume by Application (2017-2028)
6.2 Global Neurological Disorder Drugs Revenue by Application (2017-2028)
6.3 Global Neurological Disorder Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Neurological Disorder Drugs Sales by Type (2017-2028)
7.2 North America Neurological Disorder Drugs Sales by Application (2017-2028)
7.3 North America Neurological Disorder Drugs Market Size by Country
7.3.1 North America Neurological Disorder Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Neurological Disorder Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Neurological Disorder Drugs Sales by Type (2017-2028)
8.2 Europe Neurological Disorder Drugs Sales by Application (2017-2028)
8.3 Europe Neurological Disorder Drugs Market Size by Country
8.3.1 Europe Neurological Disorder Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Neurological Disorder Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Neurological Disorder Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Neurological Disorder Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Neurological Disorder Drugs Market Size by Region
9.3.1 Asia-Pacific Neurological Disorder Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neurological Disorder Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Neurological Disorder Drugs Sales by Type (2017-2028)
10.2 South America Neurological Disorder Drugs Sales by Application (2017-2028)
10.3 South America Neurological Disorder Drugs Market Size by Country
10.3.1 South America Neurological Disorder Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Neurological Disorder Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Neurological Disorder Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Neurological Disorder Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Neurological Disorder Drugs Market Size by Country
11.3.1 Middle East & Africa Neurological Disorder Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neurological Disorder Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Neurological Disorder Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neurological Disorder Drugs
12.3 Neurological Disorder Drugs Production Process
12.4 Neurological Disorder Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neurological Disorder Drugs Typical Distributors
13.3 Neurological Disorder Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---